期刊文献+

建立高分辨熔解曲线分析法检测SF3B1基因突变 被引量:2

Detection of SF3B1 mutations using high-resolution melting analysis
下载PDF
导出
摘要 目的:建立高分辨熔解曲线分析法(high-resolution melting analysis,HRMA),检测骨髓增生异常综合征(my-elodysplastic syndrome,MDS)患者中SF3B1基因的突变。方法:针对SF3B1基因热点突变位点(密码子E622、H662、K666和K700)设计PCR扩增引物,建立带有温度内标校准品的PCR扩增反应体系,对30例初诊MDS患者的骨髓标本进行PCR扩增,应用HRMA对相应PCR产物进行突变检测,并对HRMA检测结果进行DNA测序验证。结果:HR-MA检测发现2例MDS患者存在异常的熔解曲线,经DNA测序验证1例为K666M杂合子突变,另1例为K700E杂合子突变。所建立的HRMA技术检测SF3B1基因突变的灵敏度为0.05(5%)。结论:成功建立检测SF3B1基因突变的HRMA技术,可快速筛查MDS标本中的SF3B1基因突变。 Objective: To establish high-resolution melting analysis(HRMA)assay and detect the SF3B1 mutations in patients with myelodysplastic syndrome(MDS).Methods: The PCR amplification systems with internal temperature calibrators were established with specific PCR primers against four hotspot mutation sites of SF3B1 gene(E622,H662,K666,and K700).Thirty MDS samples were amplified and analyzed by using HRMA technique.The results of HRMA were verified by DNA sequencing.Results: Abnormal melting curves were observed by HRMA assay in two MDS samples.DNA sequencing confirmed that these two samples harbored heterozygous K666M mutation and K700E mutation,respectively.The sensitivity of HRMA assay could reach 0.05.Conclusion: The HRMA assay for detecting SF3B1 mutations was established successfully and could be used to screen SF3B1 mutations rapidly in patients with MDS.
出处 《江苏大学学报(医学版)》 CAS 2013年第1期49-52,共4页 Journal of Jiangsu University:Medicine Edition
基金 国家自然科学基金资助项目(81270630) 江苏省自然科学基金资助项目(BK2009206) 江苏省科技厅临床医学科技专项资金资助项目(BL2012056) 江苏省"333工程"资助项目(BRA2011085) 2010年镇江市医学重点人才项目 镇江市社会发展资助项目(SH2011056)
关键词 高分辨率熔解曲线分析 SF3B1 基因突变 骨髓增生异常综合征 high-resolution melting analysis SF3B1 gene mutation myelodysplastic syndrome
  • 相关文献

参考文献15

  • 1Pajares M J, Ezponda T, Catena R, et al. Alternative splicing: an emerging topic in molecular and clinical on- cology [ J 1. Lancet Oncol, 2007, 8 (4) :349 - 357.
  • 2David C J, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged [J]. Genes Dev, 2010, 24(21):2343-2364.
  • 3Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer[ J]. EMBO Rep, 2008, 9(11) :1087 - 1093.
  • 4Golas MM, Sander B, Will CL, et al. Molecular architec- ture of the multiprotein splicing factor SF3b[ J]. Science, 2003, 300(5621 ) :980 - 984.
  • 5Yoshida K, Sanada M, Shiraishi Y, et al. Frequent path- way mutations of splicing machinery in mye/odysplasia [J]. Nature, 2011, 478(7367):64-69.
  • 6Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts [J]. NEnglJMed, 2011, 365(15) :1384-1395.
  • 7Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical signifieance of SF3B1 mutations in myelodysplastic syn- dromes and myelodysplastic/myeloproliferative neoplasms [J]. Blood, 2011, 118(24) :6239 -6246.
  • 8Damnl F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prog- nostic implications [J]. Leukemia, 2012, 26 ( 5 ) : 1137 - 1140.
  • 9Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value[J]. Blood, 2012, 119(2) :569 -572.
  • 10Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia[ J ]. N Engl J Med, 2011, 365(26) :2497 -2506.

同被引文献29

  • 1Delhommeau F, Dupont S, Della Valle V, et al. Mutation inTET2 in myeloid cancers[ J]. N Engl J Med,2009,360 (22):2289-301.
  • 2Ley T J, Ding L, Walter M J, et al. DNMT3A mutations in acutemyeloid leukemia [J]. N Engl J Med, 2010,363 ( 25 ) : 2424 -33.
  • 3Thol F,Weissinger E M, Krauter J, et al. IDH1 mutations in pa-tients with myelodysplastic syndromes are associated with an unfa-vorable prognosis[i]. Haeraatologica, 2010,95(10) :1668 -74.
  • 4Boultwood J,Perry J,Pellagatti A,et al. Frequent mutation of thepolycomb-associated gene ASXL1 in the myelodysplastic syn-dromes and in acute myeloid leukemia [ J]. Leukemia,2010,24(5):1062-5.
  • 5Harada H, Harada Y,Niimi H, et al. High incidence of somaticmutations in the AML1/RUNX1 gene in myelodysplastic syndromeand low blast percentage myeloid leukemia with myelodysplasia[J]. Blood,2004,103 (6):2316-24.
  • 6Yoshida K, Sanada M, Shiraishi Y,et al. Frequent pathway muta-tions of splicing machinery in myelodysplasia[ J]. Nature,2011,478(7367):64 -9.
  • 7Visconte V, Rogers H J, Singh J,et al. SF3B1 haploinsufficiencyleads to formation of ring sideroblasts in myedysplastic syndromes[J]. Blood,2012,120(6) : 3173 -86.
  • 8Papaemmanuil E, Cazzola M, Boultwood J,et al. Somatic SF3B1mutation in myelodysplasia with ring sideroblasts [ J ]. N Engl JMed,2011,365(15) :1384 -95.
  • 9Malcovati L,Papaemmanuil E, Bowen D T,et al. Clinical signifi-cance of SF3B1 mumdons in myelodysplastic syndromes and myelo-dysplastic myeloproliferative neoplasms [ J ]. Blood, 2011,118.24):6239-46.
  • 10Yokoi A, Kotake Y, Takahashi K,et al. Biological validation thatSF3b is a target of the antitumor macrolide pladienolide [ J ].FEBS J,2011, 278(24) : 4870 -80.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部